Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada

  • Oliver F. BatheEmail author
  • Kelly Warren Burak
Part of the Current Clinical Oncology book series (CCO)


The Tom Baker Cancer Centre and the University of Calgary serve as a tertiary referral resource for about 1.5 million people. Virtually all hepatobiliary tumors from Southern Alberta are seen by our group, which consists of surgeons, hepatologists, gastroenterologists, interventional and diagnostic radiologists, and medical oncologists. The centralized referral pattern and weekly multidisciplinary meetings provide the group with a large experience in treating patients with these tumors.


Cancer-related mortality Canada Bile duct cancer Tests mTOR 


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. 2008;, based on November 2007 SEER data submission, posted to the SEER web site; 2008.
  3. 3.
    Dixon E, Bathe O, McKay A, et al. A population based review of the outcomes following hepatic resection in a Canadian health region. Can J Surg. 2009;52:12–7.PubMedGoogle Scholar
  4. 4.
    Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42: 1208–36.PubMedCrossRefGoogle Scholar
  5. 5.
    DiBisceglie A, Lyra A, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98:2060–3.Google Scholar
  6. 6.
    Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918–28.PubMedCrossRefGoogle Scholar
  7. 7.
    Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.PubMedCrossRefGoogle Scholar
  8. 8.
    Llovet J, DiBisceglie A, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.PubMedCrossRefGoogle Scholar
  9. 9.
    Llovet J, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Mazzaferro V, Regalia E, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol. 2008;15:3169–77.PubMedCrossRefGoogle Scholar
  12. 12.
    Nakajima Y, Ko S, Kanamura T, et al. Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg. 2001;192:339–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Vennarecci G, Ettorre G, Antonini M, et al. First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis. Transplant Proc. 2007;39:1857–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Ng K, Lo C, Liu C, Poon R, Chan S, Fan S. Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg. 2008;143: 68–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Mazzaferro V. Results of liver transplantation: with or without Milan criteria? Liver Transpl. 2007;13(11Suppl 2):S44–7.Google Scholar
  16. 16.
    Lam V, Ng K, Chok K, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008;207:20–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Livraghi T, Meloni F, DiStasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.PubMedCrossRefGoogle Scholar
  19. 19.
    Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Koh T, Taniguchi H, Katoh H, Kunishima S, Yamaguchi A, Yamagishi H. Are both PIVKA-II and alpha-fetoprotein necessary in follow-up management after hepatic resection for hepatocellular carcinoma? Hepatogastroenterology. 2002;49:1615–8.PubMedGoogle Scholar
  21. 21.
    Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol. 1997;64:143–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol. 2007; 21(Suppl C):5C–24C.PubMedGoogle Scholar
  23. 23.
    Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol. 2007;21 (Suppl C):25C–34C.PubMedGoogle Scholar
  24. 24.
    Wilson S, Jang H, Kim T, Burns P. Diagnosis of focal liver masses on ultrasonography: comparison of unenhanced and contrast-enhanced scans. J Ultrasound Med. 2007;26:775–87.PubMedGoogle Scholar
  25. 25.
    Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005;18:1417–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen M, Li J, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006; 243:321–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Hasegawa K, Makuuchi M, Takayama T, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589–94.PubMedCrossRefGoogle Scholar
  28. 28.
    Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs A. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33:437–47.PubMedCrossRefGoogle Scholar
  29. 29.
    Yu H, Cheng J, Lai K, et al. Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol. 2005;11:1439–44.PubMedGoogle Scholar
  30. 30.
    Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther. 2008;25:787–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Yao F, Ferrell L, Bass N, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.PubMedCrossRefGoogle Scholar
  32. 32.
    Toso C, Meeberg G, Bigam D, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83:1162–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14:1107–15.PubMedCrossRefGoogle Scholar
  34. 34.
    Villanueva A, Chiang D, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972–83. Epub 2008 Aug 20, e1-e11, ahead of print.PubMedCrossRefGoogle Scholar
  35. 35.
    Toso C, Asthana S, Bigam D, Shapiro A, Kneteman N. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma with the scientific registry of transplant recipients database. Hepatology. 2009;49:832–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Dharancy S, Romano O, Lorho R, et al. Tolerability and efficacy of sorafenib in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. Hepatology. 2008;48(4 Suppl):310A.Google Scholar
  37. 37.
    Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233:385–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg. 2008;248:273–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Bathe OF, Pacheco JT, Ossi PB, et al. A subcutaneous or subfascial jejunostomy is beneficial in the surgical management of extrahepatic bile duct cancers. Surgery. 2000;127:506–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Endo I, House MG, Klimstra DS, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:2104–12.PubMedCrossRefGoogle Scholar
  41. 41.
    Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.PubMedCrossRefGoogle Scholar
  42. 42.
    Bathe OF, Pacheco JT, Ossi PB, et al. Management of hilar bile duct carcinoma. Hepatogastroenterology. 2001;48:1289–94.PubMedGoogle Scholar
  43. 43.
    Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008;15:3147–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Thelen A, Neuhaus P. Liver transplantation for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14:469–75.PubMedCrossRefGoogle Scholar
  45. 45.
    Huang JL, Biehl TR, Lee FT, Zimmer PW, Ryan Jr JA. Outcomes after resection of cholangiocellular carcinoma. Am J Surg. 2004;187:612–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol. 2008;15:590–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Allen PJ, Reiner AS, Gonen M, et al. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. HPB (Oxford). 2008;10:341–6.CrossRefGoogle Scholar
  48. 48.
    Thomas H, Heaton ND. Late recurrence after surgery for cholangiocarcinoma: implications for follow-up? Hepatobiliary Pancreat Dis Int. 2008;7:544–6.PubMedGoogle Scholar
  49. 49.
    Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Verslype C, Prenen H, Van Cutsem E. The role of chemotherapy in biliary tract carcinoma. HPB (Oxford). 2008;10:164–7.CrossRefGoogle Scholar
  51. 51.
    Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002;89:1525–31.PubMedCrossRefGoogle Scholar
  52. 52.
    Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193: 384–91.PubMedCrossRefGoogle Scholar
  53. 53.
    Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008; 15:2787–94.PubMedCrossRefGoogle Scholar
  54. 54.
    Cox H, Ma M, Bridges R, et al. Well differentiated intrahepatic cholangiocarcinoma in the setting of biliary papillomatosis: a case report and review of the literature. Can J Gastroenterol. 2005; 19:731–3.PubMedGoogle Scholar
  55. 55.
    Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006;41:893–900.PubMedCrossRefGoogle Scholar
  56. 56.
    Kurosaki I, Hatakeyama K. Repeated hepatectomy for recurrent intrahepatic cholangiocarcinoma: report of two cases. Eur J Gastroenterol Hepatol. 2005;17:125–30.PubMedCrossRefGoogle Scholar
  57. 57.
    Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation. 2006;82:1703–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Nakata T, Kobayashi A, Miwa S, Soeda J, Miyagawa S. Impact of tumor spread to the cystic duct on the prognosis of patients with gallbladder carcinoma. World J Surg. 2007;31:155–61; discussion 162–53.Google Scholar
  59. 59.
    Dixon E, Vollmer Jr CM, Sahajpal A, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg. 2005;241:385–94.PubMedCrossRefGoogle Scholar
  60. 60.
    Giuliante F, Ardito F, Vellone M, Clemente G, Nuzzo G. Port-sites excision for gallbladder cancer incidentally found after laparoscopic cholecystectomy. Am J Surg. 2006;191:114–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Park JS, Yoon DS, Kim KS, et al. Actual recurrence patterns and risk factors influencing recurrence after curative resection with stage II gallbladder carcinoma. J Gastrointest Surg. 2007;11: 631–7.PubMedCrossRefGoogle Scholar
  62. 62.
    D’Angelica M, Dalal KM, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2008;16:806–16.PubMedCrossRefGoogle Scholar
  63. 63.
    Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008;98:485–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Chan SY, Poon RT, Lo CM, Ng KK, Fan ST. Management of carcinoma of the gallbladder: a single-institution experience in 16 years. J Surg Oncol. 2008;97:156–64.PubMedCrossRefGoogle Scholar
  65. 65.
    Tasaki K, Yamamoto H, Watanabe K, et al. Successful treatment of lymph node metastases recurring from gallbladder cancer. J Hepatobiliary Pancreat Surg. 2003;10:113–7.PubMedGoogle Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  1. 1.Division of Surgical OncologyTom Baker Cancer CentreCalgaryCanada
  2. 2.Southern Alberta Liver Transplant ClinicUniversity of Calgary Liver UnitCalgaryCanada

Personalised recommendations